Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 850 of 885 entries
View as:

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05357755 Org: User:
Start: 06/13/22 End: 04/10/23 Due: 04/10/24

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

Phase: N/A Priority: Normal
NCT ID: NCT03819049 Org: User:
Start: 06/06/19 End: 12/18/24 Due: 12/18/25

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02342249 Org: User:
Start: 12/11/14 End: 05/25/16 Due: 05/25/17

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Phase: N/A Priority: Normal
NCT ID: NCT01369355 Org: User:
Start: 09/13/11 End: 10/01/19 Due: 10/01/20

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

Phase: N/A Priority: Normal
NCT ID: NCT04589026 Org: User:
Start: 10/21/20 End: 05/06/21 Due: 05/06/22

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03384654 Org: User:
Start: 05/14/18 End: 09/27/22 Due: 09/27/23

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Phase: N/A Priority: Normal
NCT ID: NCT01273467 Org: User:
Start: 12/31/10 End: 07/31/13 Due: 07/31/14

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT01480388 Org: User:
Start: 12/31/11 End: 03/31/14 Due: 03/31/15

A Study of JNJ-64251330 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04552197 Org: User:
Start: 09/02/20 End: 12/29/20 Due: 12/29/21

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT02117505 Org: User:
Start: 04/30/14 End: 06/30/14 Due: 06/30/15

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02609776 Org: User:
Start: 05/24/16 End: 12/31/25 Due: 12/31/26

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT04609826 Org: User:
Start: 11/26/20 End: 07/31/25 Due: 07/31/26

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Phase: N/A Priority: Normal
NCT ID: NCT04312672 Org: User:
Start: 07/31/17 End: 11/18/26 Due: 11/18/27

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Phase: N/A Priority: Normal
NCT ID: NCT04929210 Org: User:
Start: 08/30/21 End: 11/10/26 Due: 11/10/27

A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02670395 Org: User:
Start: 04/30/16 End: 09/30/16 Due: 09/30/17

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02475161 Org: User:
Start: 06/30/15 End: 07/31/15 Due: 07/31/16

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05827874 Org: User:
Start: 04/12/23 End: 10/04/23 Due: 10/04/24

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01569750 Org: User:
Start: 06/14/12 End: 09/04/14 Due: 09/04/15

A Study of JNJ-70075200 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04782661 Org: User:
Start: 03/01/22 End: 09/23/22 Due: 09/23/23

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02609789 Org: User:
Start: 12/31/15 End: 09/30/18 Due: 09/30/19

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01867762 Org: User:
Start: 09/09/13 End: 09/01/14 Due: 09/01/15

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT01678573 Org: User:
Start: 07/31/12 End: 09/30/12 Due: 09/30/13

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02218073 Org: User:
Start: 10/31/14 End: 12/31/14 Due: 12/31/15

A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT02674295 Org: User:
Start: 03/31/16 End: 08/31/16 Due: 08/31/17

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05364554 Org: User:
Start: 06/10/22 End: 09/29/23 Due: 09/29/24